A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
about
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A randomised, double-blind, tr ...... diabetes and renal impairment.
@en
A randomised, double-blind, tr ...... diabetes and renal impairment.
@nl
type
label
A randomised, double-blind, tr ...... diabetes and renal impairment.
@en
A randomised, double-blind, tr ...... diabetes and renal impairment.
@nl
prefLabel
A randomised, double-blind, tr ...... diabetes and renal impairment.
@en
A randomised, double-blind, tr ...... diabetes and renal impairment.
@nl
P2093
P2860
P356
P1476
A randomised, double-blind, tr ...... diabetes and renal impairment
@en
P2093
Antonio Chacra
Edward A O'Neill
Geraldine Mendizabal
Lucila Durlach
Samuel S Engel
Shailaja Suryawanshi
Zachary Zimmer
P2860
P356
10.1111/IJCP.12955
P50
P577
2017-04-27T00:00:00Z